Abstracts tagged "osteo-anabolics and osteoporosis"

Abstract Number: 1890 • ACR/ARHP Annual Meeting 2017
Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed By 24 Months of Alendronate
Kenneth Saag¹, Paul D Miller², Felicia Cosman^3,4, Lorraine A Fitzpatrick⁵, Gary Hattersley⁶, Robert Gut⁶, Bruce Mitlak⁶, John P Bilezikian⁴ and Robin K Dore⁷, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Colorado Center for Bone Research, Lakewood, CO, ³Helen Hayes Hospital, West Haverstraw, NY, ⁴Columbia University College of Physicians and Surgeons, New York, NY, ⁵Chief Medical Officer, Radius Health, Inc., Waltham, MA, ⁶Radius Health, Inc., Waltham, MA, ⁷Robin K Dore, MD, Inc., Tustin, CA
Background/Purpose: In the ACTIVE phase III trial, postmenopausal women with osteoporosis were randomized 1:1:1 to abaloparatide (ABL; n=824), blinded placebo (PBO; n=821), or open-label teriparatide…
Abstract Number: 338 • ACR/ARHP Annual Meeting 2016
Abaloparatide-SC Significantly Reduces Vertebral and Nonvertebral Fractures and Increases Bone Mineral Density (BMD) Regardless of Age, BMD T-Score, or Prior Fracture at Baseline
F Cosman¹, Gary Hattersley², PD Miller³, Ming-Yu Hu⁴, Luis Augusto Tavares Russo⁵, Bente Riis⁶, Greg Williams⁷ and Lorraine Fitzpatrick⁸, ¹Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY, ²Research, Radius Health, Inc., Waltham, MA, ³Colorado Center for Bone Research, Lakewood, CO, ⁴Biometrics, Radius Health, Inc., Waltham, MA, ⁵CCBR Brasil, Rua Mena Barreto, 33 Botofogo, 22271, Rio de Janeiro, Brazil, ⁶Nordic Biosciences A/S, 2730 Herlev, Denmark, ⁷Clinical Development, Radius Health, Inc., Waltham, MA, ⁸Chief Medical Officer, Radius Health, Inc., Waltham, MA
Background/Purpose: Abaloparatide is a novel 34 amino acid peptide created to be a potent and selective activator of the PTH 1 receptor signaling pathway and…